FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Running kidney-disease Phase 2 trials alongside Phase 1 programmes in oncology and ophthalmology.

  • Reported completion of Phase 2 dosing in contrast-induced kidney injury and first Phase 1 data for APX-343A. Source

Roles often seen at this stageClinical & PV · Regulatory affairs · Research & development

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Aptabio Therapeutics

A drug developer using NOX-inhibitor/CAF-modulation and Apta-DC platforms for kidney disease, oncology and ophthalmology.

Isuzinaxib

Phase 2

In a Korean Phase 2b for diabetic kidney disease; dosing in its global Phase 2 for contrast-induced acute kidney injury finished in April 2026.

APX-343A

Phase 1

An immuno-oncology candidate whose first human Phase 1 data from Korea were presented at ASCO 2026.

ABF-101

Phase 1

An oral candidate for age-related macular degeneration; US FDA cleared its Phase 1 IND in October 2025.

Completion reported

Completed dosing in the global Phase 2 of isuzinaxib for contrast-induced acute kidney injury.

Completion reported

Presented first Phase 1 data for APX-343A at ASCO 2026.

Completion reported

Received US FDA clearance of the Phase 1 IND for ABF-101.

Official role guide

Aptabio Therapeutics careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 압타바이오, 美 JP모간 헬스케어·바이오텍 쇼케이스 간다 ↗한국경제 · Published 2025-12-22 · Sources checked 2026-11-18 · Original unavailable
  2. 압타바이오, 'BIO USA 2026'서 기술이전 논의 본격화 ↗약업신문 · Published 2026-06-04 · Sources checked 2026-11-18 · Original unavailable